Skip to main content
. 2021 Nov 2;9(1):e1098. doi: 10.1212/NXI.0000000000001098

Figure 3. Rituximab Treatment Response: Clinical Status, NF155 Titers, and sNfL Levels.

Figure 3

Clinical improvement is present in patients treated with first-line therapies or rituximab but only the rituximab-treated group improved significantly. Anti-NF155 titers and sNfL levels decreased only in rituximab-treated group. The line in the center represents the median value, and the whiskers indicate the interquartile range. IVIg = IV immunoglobulin; mRS= modified Rankin Scale; NF155= neurofascin-155; sNfL= serum neurofilament light chain.